학술논문

Fertility-sparing surgery in children and adolescents with borderline ovarian tumors: a retrospective study
Document Type
Report
Source
Journal of Ovarian Research. May 8, 2024, Vol. 17 Issue 1
Subject
Children
Ovarian cancer -- Development and progression
Obstetrics
Surgery
Language
English
ISSN
1757-2215
Abstract
Objective To describe the characteristics of children and adolescents with borderline ovarian tumors (BOTs) and evaluate the efficacy and safety of fertility-sparing surgery (FSS) in these patients. Methods Patients with BOTs younger than 20 years who underwent FSS were included in this study. Results A total of 34 patients were included, with a median patient age of 17 (range, 3-19) years; 97.1% (33/34) of cases occurred after menarche. Of the patients, 82.4% had mucinous borderline tumors (MBOTs), 14.7% had serous borderline tumors (SBOTs), and 2.9% had seromucinous borderline tumor (SMBOT). The median tumor size was 20.4 (range, 8-40)cm. All patients were at International Federation of Gynecology and Obstetrics stage I and all underwent FSS: cystectomy (unilateral ovarian cystectomy, UC, 14/34, 41.2% and bilateral ovarian cystectomy, BC, 1/34, 2.9%), unilateral salpingo-oophorectomy (USO; 18/34; 52.9%), or USO + contralateral ovarian cystectomy (1/34; 2.9%). The median follow-up time was 65 (range, 10-148) months. Recurrence was experienced by 10 of the 34 patients (29.4%). One patient with SBOT experienced progression to low-grade serous carcinoma after the third relapse. Two patients had a total of four pregnancies, resulting in three live births. The recurrence rate of UC was significantly higher in MBOTs than in USO (p = 0.005). The 5-year disease-free survival rate was 67.1%, and the 5-year overall survival rate was 100%. Conclusions Fertility-sparing surgery is feasible and safe for children and adolescents with BOTs. For patients with MBOTs, USO is recommended to lower the risk of recurrence. Keywords: Borderline ovarian tumor, Fertility-sparing surgery, Children, Adolescent
Author(s): Jiayuan Zhao[sup.1], Dan Wang[sup.1], Ruojiao Wang[sup.2], Yonglan He[sup.3], Congwei Jia[sup.4], Lingya Pan[sup.1], Shuiqing Ma[sup.1], Ming Wu[sup.1], Weidi Wang[sup.1], Xinghan Cheng[sup.1], Junjun Yang[sup.1] and Yang Xiang[sup.1] Introduction Borderline ovarian tumors [...]